Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials.


Wei, L; Ebrahim, S; Bartlett, C; Davey, PD; Sullivan, FM; MacDonald, TM; (2005) Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ, 330 (7495). p. 821. ISSN 1468-5833 DOI: https://doi.org/10.1136/bmj.38398.408032.8F

[img]
Preview
Text - Published Version
License: Creative Commons Attribution Non-commercial

Download (94kB) | Preview

Abstract

OBJECTIVE: To compare the social and demographic profiles of patients who receive statin treatment after myocardial infarction and patients included in randomised trials. To estimate the effect of statin use in community based patients on subsequent all cause mortality and cardiovascular recurrence, contrasting effects with trial patients. DESIGN: Observational cohort study using a record linkage database. SETTING: Tayside, Scotland (population size and characteristics: about 400,000, mixed urban and rural). SUBJECTS: 4892 patients were discharged from hospital after their first myocardial infarction between January 1993 and December 2001. 2463 (50.3%) were taking statins during an average follow-up of 3.7 years (3.1% in 1993 and 62.9% in 2001). MAIN OUTCOME MEASURES: All cause mortality and recurrence of cardiovascular events. RESULTS: 319 deaths occurred in the statin treated group (age adjusted rate 4.1 per 100 person years, 95% confidence interval 3.2 to 4.9), and 1200 in the statin untreated group (12.7 per 100 person years, 11.1 to 14.3). More older people and women were represented in the population of patients treated with statins than among those recruited into clinical trials (mean age 67.8 v 59.8; women 39.6% v 16.9%, respectively). The effects of statins in routine clinical practice were consistent with, and similar to, those reported in clinical trials (adjusted hazard ratio for all cause mortality 0.69, 95% confidence interval 0.59 to 0.80; adjusted hazard ratio for cardiovascular recurrence 0.82, 0.71 to 0.95). CONCLUSIONS: The community effectiveness of statins in those groups that were not well represented in clinical trials was similar to the efficacy of statins in these trials.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
Research Centre: Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 15790616
Web of Science ID: 228273900018
URI: http://researchonline.lshtm.ac.uk/id/eprint/12771

Statistics


Download activity - last 12 months
Downloads since deposit
186Downloads
278Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item